RNA-binding proteins (RBPs) critically regulate post-transcriptional gene expression, yet their roles in chemotherapy resistance remain underexplored. Here, through a targeted siRNA screen of 40 RBM family members, we identified RNA-binding motif protein 8 A (RBM8A) as central orchestrator of oxaliplatin-induced DNA...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial...
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable...
AbstractObjective The purpose of this study was to evaluate the effect of sodium–glucose cotransporter 2 inhibitors on estimated glomerular filtration rate and serum creatinine among patients with type 2 diabetes mellitus and chronic kidney disease receiving treatment in a secondary...
Abstract Cancer remains a major global health challenge, requiring the development of novel therapeutic agents with high efficacy and minimal side effects. In this study, we designed and synthesised a series of hybrid molecules incorporating triazoles, Schiff bases and substituted...
SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of...
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target...
